ADMA Biologics Inc (NASDAQ: ADMA) presents a compelling opportunity for investors seeking exposure to the biotechnology sector, specifically within the realm of plasma-derived biologics. With a market capitalization of $3.84 billion, ADMA is steadily paving its path in the healthcare industry, focusing on critical treatments for immune deficiencies and infectious diseases.

The company, headquartered in Ramsey, New Jersey, is renowned for its flagship products such as BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies addressing primary humoral immunodeficiency. Additionally, ADMA offers Nabi-HB, a treatment for acute exposure to Hepatitis B, and maintains a forward-looking pipeline of plasma-derived…